Peer-Reviewed Journal Details
Mandatory Fields
Diaz, ACDC;Malone, K;Shearer, JA;Moore, AC;Waeber, C
2022
July
Frontiers in pharmacology
Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities
Validated
WOS: 1 ()
Optional Fields
ACUTE ISCHEMIC-STROKE IMMUNE MODULATOR FINGOLIMOD CENTRAL-NERVOUS-SYSTEM MULTIPLE-SCLEROSIS SPHINGOSINE KINASE REPERFUSION INJURY FTY720 FINGOLIMOD ORAL FINGOLIMOD INFLAMMATION EFFICACY
13
Preclinical data indicate that fingolimod improves outcome post-ischaemia. This study used a rigorous study design in normal male C57BL/6JOlaHsd mice and in mice with common stroke comorbidities to further evaluate the translational potential of fingolimod. Stroke was induced via middle cerebral artery electrocoagulation in 8-9-week old mice (young mice), 18 month old mice (aged mice), and in high-fat diet-fed 22-week old ApoE-/- mice (hyperlipidaemic mice). Recovery was evaluated using motor behavioural tests 3 and 7 days after stroke. Tissue damage was evaluated at 7 days. A lower dose of fingolimod, 0.5 mg/kg, but not 1 mg/kg, increased lesion size but decreased ipsilateral brain atrophy in younger mice, without an effect on behavioural outcomes. Fingolimod-treated aged mice showed a significant improvement over saline-treated mice in the foot fault test at 7 days. Fingolimod-treated hyperlipidaemic mice showed a decreased infarct size but no difference in behavioural performance. Increasing fingolimod treatment time to 10 days showed no benefit in young mice. Pooled data showed that fingolimod improved performance in the foot fault test. Flow cytometry studies showed that fingolimod had marked effects on T cell frequencies in various tissues. The results show that the effects of fingolimod in stroke are less robust than the existing literature might indicate and may depend on the inflammatory status of the animals.
LAUSANNE
1663-9812
10.3389/fphar.2022.920449
Grant Details